News Column

New Rheumatoid Arthritis Findings from DRFZ Reported [Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results...

August 20, 2014



New Rheumatoid Arthritis Findings from DRFZ Reported [Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients]

By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Autoimmune Diseases are presented in a new report. According to news reporting out of Berlin, Germany, by NewsRx editors, research stated, "The aim of this study was to evaluate the safety and efficacy of rituximab (RTX) in a large cohort of patients with rheumatoid arthritis in routine care, and to monitor changes in daily practice since the introduction of RTX therapy. This was a multicentre, prospective, non-interventional study conducted under routine practice conditions in Germany."

Our news journalists obtained a quote from the research from DRFZ, "Efficacy was evaluated using Disease Activity Score in 28 joints (DAS28) and Health Assessment Questionnaire-Disability Index (HAQ-DI). Safety was assessed by recording adverse drug reactions (ADRs). Physician and patient global efficacy and tolerability assessments were also evaluated. Overall, 2,484 patients (76.7% female, mean age 56.4 years, mean disease duration 11.7 years) received RTX treatment (22.7% monotherapy). The total observation period was approximately six-years (median follow-up 14.7 months). RTX treatment led to improvements in DAS28 and HAQ-DI that were sustained over multiple courses. DAS28 improvements positively correlated with higher rheumatoid factor levels up to 50 IU/ml. Response and tolerability were rated good/very good by the majority of physicians and patients. Mean treatment intervals were 10.5 and 6.8 months for the first and last 400 enrolled patients, respectively. Infections were the most frequently reported ADRs (9.1%; 11.39/100 patient-years); approximately 1% of patients per course discontinued therapy due to ADRs. Prolonged RTX treatment in routine care is associated with good efficacy and tolerability, as measured by conventional parameters and by physicians' and patients' global assessments. Rheumatoid factor status served as a distinct and quantitative biomarker of RTX responsiveness."

According to the news editors, the research concluded: "With growing experience, physicians repeated treatments earlier in patients with less severe disease activity."

For more information on this research see: Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Research & Therapy, 2014;16(2):292-300. Arthritis Research & Therapy can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; Arthritis Research & Therapy - arthritis-research.com/)

Our news journalists report that additional information may be obtained by contacting J. Wendler, DRFZ Berlin, D-10098 Berlin, Germany. Additional authors for this research include G.R. Burmester, H. Sorensen, A. Krause, C. Richter, H.P. Tony, A. Rubbert-Roth, P. Bartz-Bazzanella, S. Wassenberg, I. Haug-Rost and T. Dorner (see also Autoimmune Diseases).

Keywords for this news article include: Antineoplastic Monoclonal Antibodies, Antirheumatics, Biotechnology, Drugs, Berlin, Europe, Germany, Therapy, Rituximab, Joint Diseases, Medical Devices, Autoimmune Diseases, Rheumatoid Arthritis, Musculoskeletal Diseases, CD20 Monoclonal Antibodies, Tyrosine Kinase Inhibitors

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters